{"bill": {"#text": "\n\t", "form": {"current-chamber": {"#tail": "\n\t\t", "#text": "IN THE HOUSE OF REPRESENTATIVES"}, "#text": "\n\t\t", "congress": {"#tail": "\n\t\t", "#text": "113th CONGRESS"}, "#tail": "\n\t", "legis-num": {"#tail": "\n\t\t", "#text": "H. R. 842"}, "official-title": {"#tail": "\n\t", "#text": "To expand the research activities of the National\n\t\t  Institutes of Health with respect to functional gastrointestinal and motility\n\t\t  disorders, and for other purposes."}, "session": {"#tail": "\n\t\t", "#text": "1st Session"}, "distribution-code": {"#tail": "\n\t\t", "@display": "yes", "#text": "I"}, "action": {"action-date": {"#tail": "\n\t\t\t", "@date": "20130226", "#text": "February 26, 2013"}, "#tail": "\n\t\t", "action-desc": {"#tail": "\n\t\t", "#text": "\n        ", "committee-name": {"#tail": "\n      ", "@committee-id": "HIF00", "#text": "Committee on Energy and\n\t\t\t Commerce"}, "sponsor": {"#tail": "\n\t\t\t (for himself and ", "#text": "Mr. Sensenbrenner", "@name-id": "S000244"}, "cosponsor": {"#tail": ") introduced\n\t\t\t the following bill; which was referred to the\n\t\t\t ", "#text": "Mr. Moran", "@name-id": "M000933"}}, "#text": "\n\t\t\t"}, "legis-type": {"#tail": "\n\t\t", "#text": "A BILL"}}, "@bill-stage": "Introduced-in-House", "@bill-type": "olc", "@dms-id": "HFB29EFCFA4134000A45F969EBF8522C8", "@public-private": "public", "legis-body": {"#tail": "\n", "@style": "OLC", "section": [{"@section-type": "section-one", "#tail": "\n    ", "text": {"#tail": "\n\t\t", "quote": {"short-title": {"#tail": "\n        ", "#text": "Functional Gastrointestinal and\n\t\t\t Motility Disorders Research Enhancement Act of\n\t\t\t 2013"}, "#tail": ".", "#text": "\n          "}, "#text": "This Act may be cited as the\n\t\t\t ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n      ", "#text": "Short title"}, "#text": "\n      ", "@id": "HAD2B9D71CA02466AB488B8491E35F2AD"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " finds the following:", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}, "#text": "\n        ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": "\n      ", "#text": "Findings"}, "paragraph": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "Functional\n\t\t\t gastrointestinal and motility disorders (FGIMDs) are chronic conditions\n\t\t\t associated with increased sensitivity of the GI tract, abnormal motor\n\t\t\t functioning, and brain-gut dysfunction."}, "enum": {"#tail": "\n        ", "#text": "(1)"}, "@id": "HC29E790F377C4BBCABFD3B316C0CF245", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "FGIMDs are\n\t\t\t characterized by symptoms in the GI tract including pain or discomfort, nausea,\n\t\t\t vomiting, diarrhea, constipation, incontinence, problems in the passage of food\n\t\t\t or feces, or a combination of these symptoms."}, "enum": {"#tail": "\n        ", "#text": "(2)"}, "@id": "H56B11C722F4C48F6A2408D5DABD490A1", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "FGIMDs include\n\t\t\t conditions such as dysphagia, gastroesophageal reflux disease, dyspepsia,\n\t\t\t cyclic vomiting syndrome, gastroparesis, irritable bowel syndrome (IBS),\n\t\t\t Hirschsprung\u2019s disease, chronic intestinal pseudo-obstruction, bowel\n\t\t\t incontinence, and many others, which affect the esophagus, stomach,\n\t\t\t gallbladder, small and large intestine, and anorectal areas of the body."}, "enum": {"#tail": "\n        ", "#text": "(3)"}, "@id": "H54B6D28DB8CA4FEABC890E27D222DD80", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "The severity of\n\t\t\t FGIMDs ranges from mildly uncomfortable to debilitating and in some cases\n\t\t\t life-threatening."}, "enum": {"#tail": "\n        ", "#text": "(4)"}, "@id": "HCD671DF50088492AA1B35E90A9BA9D38", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "Effective\n\t\t\t treatments for the multiple symptoms of FGIMDs are lacking, and while sufferers\n\t\t\t frequently use a variety of medications and therapies for symptoms, few\n\t\t\t patients report satisfaction with available treatments."}, "enum": {"#tail": "\n        ", "#text": "(5)"}, "@id": "H060F46680E554000BCFDB282FE3CF508", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "Patients with\n\t\t\t FGIMDs frequently suffer for years before receiving an accurate diagnosis,\n\t\t\t exposing them to unnecessary and costly tests and procedures including\n\t\t\t surgeries, as well as needless suffering and expense."}, "enum": {"#tail": "\n        ", "#text": "(6)"}, "@id": "HFCAFA20893BA45D3AC88B4F1C5993AB0", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "The economic\n\t\t\t impact of FGIMDs is high. The annual cost in the United States for IBS alone is\n\t\t\t estimated to be between $1.7 billion and $10 billion in direct medical costs\n\t\t\t (excluding prescription and over-the-counter medications) and $20 billion in\n\t\t\t indirect medical costs."}, "enum": {"#tail": "\n        ", "#text": "(7)"}, "@id": "HB56E13F4CFC54D449D6AA3E265C06F47", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "FGIMDs frequently\n\t\t\t take a toll on the workplace, as reflected in work absenteeism, lost\n\t\t\t productivity, and lost opportunities for the individual and society."}, "enum": {"#tail": "\n        ", "#text": "(8)"}, "@id": "H8B8DC464F8BF46C2A5FAF77BFA358FF2", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "Gastrointestinal\n\t\t\t symptoms consistent with functional gastrointestinal disorders such as IBS and\n\t\t\t functional dyspepsia have been recognized as a serious and disabling issue for\n\t\t\t military veterans, particularly those who have been deployed."}, "enum": {"#tail": "\n        ", "#text": "(9)"}, "@id": "H227CC5A4F26D42C68EDF7BAB5BF290FE", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "FGIMDs affect\n\t\t\t individuals of all ages including children, and pediatric FGIMDs can be\n\t\t\t particularly serious, leading to a lifetime of painful symptoms and medical\n\t\t\t expenses associated with management of chronic illness or death."}, "enum": {"#tail": "\n        ", "#text": "(10)"}, "@id": "HA9883414E7ED470D87F1C693945552A3", "#text": "\n        "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " identified\n\t\t\t comprehensive research goals related to FGIMDs in its April 2009 report to\n\t\t\t ", "@entity-parent-id": "7529", "@entity-type": "federal-body", "#text": "National\n\t\t\t Institutes of Health\u2019s National Commission on Digestive Diseases", "@value": "National Commission on Digestive Diseases"}, {"#tail": " and the American public entitled ", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}], "#text": "The ", "quote": {"#tail": ".", "#text": "Opportunities and Challenges\n\t\t\t in Digestive Diseases Research: Recommendations of the National Commission on\n\t\t\t Digestive Diseases"}}, "enum": {"#tail": "\n        ", "#text": "(11)"}, "@id": "H5F087C95803742E49F3DF452D012D066", "#text": "\n        "}], "#text": "\n      ", "@id": "HB2BA56449D6B4693984D0D006E004994"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "#text": "\n        ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by adding at the end the\n\t\t\t following:", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "Part B of title IV of the Public Health\n\t\t\t Service Act", "@value": "Public Health Service Act/t:IV/pt:B"}, {"#tail": ")", "@entity-type": "uscode", "#text": "42 U.S.C. 284 et seq.", "@value": "usc/42/284/etseq"}], "@entity-type": "law-citation", "#text": "\n          "}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "3."}, "header": {"#tail": "\n      ", "#text": "Functional\n\t\t\t gastrointestinal and motility disorders research enhancement"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n      ", "#text": "."}, "#tail": "\n\t\t", "section": {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may expand, intensify,\n\t\t\t\tand coordinate the activities of the ", "@entity-type": "federal-body", "#text": "Director of NIH", "@entity-id": "7529"}, {"#tail": " with respect\n\t\t\t\tto functional gastrointestinal and motility disorders (in this section referred\n\t\t\t\tto as ", "@entity-type": "federal-body", "#text": "National Institutes of Health", "@entity-id": "7529"}], "term": {"#tail": ") by\u2014", "#text": "FGIMDs"}, "#text": "The ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n          ", "#text": "409K."}, "header": {"#tail": "\n          ", "#text": "Functional\n\t\t\t\tgastrointestinal and motility disorders"}, "paragraph": [{"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " relating to FGIMDs;", "@entity-parent-id": "7529", "@entity-type": "federal-body", "#text": "National Commission on Digestive Diseases", "@value": "National Commission on Digestive Diseases"}, "#text": "expanding basic\n\t\t\t\tand clinical research into FGIMDs by implementing the research recommendations\n\t\t\t\tof the "}, "enum": {"#tail": "\n            ", "#text": "(1)"}, "@display-inline": "no-display-inline", "#text": "\n            ", "@id": "HC8D26286C8AF429E82C69C7184545288"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "providing support\n\t\t\t\tfor the establishment of up to five centers of excellence on FGIMDs at leading\n\t\t\t\tacademic medical centers throughout the country to carry out innovative basic,\n\t\t\t\ttranslational, and clinical research focused on FGIMDs;"}, "enum": {"#tail": "\n            ", "#text": "(2)"}, "@id": "H17E9543D6BC948EEBB1ECAAC58C49F5D", "#text": "\n            "}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", the ", "@entity-parent-id": "7529", "@entity-type": "federal-body", "#text": "National Institute of Diabetes and Digestive and Kidney\n\t\t\t\tDiseases", "@value": "National Institute of Diabetes and Digestive and Kidney Diseases"}, {"#tail": ", the ", "@entity-parent-id": "7529", "@entity-type": "federal-body", "#text": "Office of Research on Women\u2019s Health", "@value": "Office of Research on Women's Health"}, {"#tail": ", and other Institutes and Centers of the National Institutes of\n\t\t\t\tHealth;", "@entity-parent-id": "7529", "@entity-type": "federal-body", "#text": "Office of Rare Disease\n\t\t\t\tResearch", "@value": "Office of Rare Diseases Research"}], "#text": "exploring collaborative research\n\t\t\t\topportunities among the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(3)"}, "@id": "HBE674AB9297B41E3A6B3000FA8D4EDEB", "#text": "\n            "}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "s to provide the necessary funding for\n\t\t\t\tcontinued expansion and advancement of the FGIMDs research portfolio through\n\t\t\t\tintramural and extramural research;", "@entity-parent-id": "7529", "@entity-type": "federal-body", "#text": "National Institute of\n\t\t\t\tDiabetes and Digestive and Kidney Disease", "@value": "National Institute of Diabetes and Digestive and Kidney Diseases"}, "#text": "directing the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(4)"}, "@id": "HFF0F818107904CA8BC6E310E7A4B01FB", "#text": "\n            "}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " and the ", "@entity-parent-id": "7529", "@entity-type": "federal-body", "#text": "National Institute of\n\t\t\t\tDiabetes and Digestive and Kidney Diseases", "@value": "National Institute of Diabetes and Digestive and Kidney Diseases"}, {"#tail": " to expand research\n\t\t\t\tinto FGIMDs that impact children, such as Hirschsprung\u2019s disease and cyclic\n\t\t\t\tvomiting syndrome, and maternal health, such as fecal incontinence; and", "@entity-parent-id": "7529", "@entity-type": "federal-body", "#text": "Eunice Kennedy Shriver\n\t\t\t\tNational Institute of Child Health and Human Development", "@value": "Eunice Kennedy Shriver National Institute of Child Health and Human Development"}], "#text": "directing the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(5)"}, "@id": "HB7797958B4664A9EA63CBD95E8CB7715", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " and the ", "@entity-type": "federal-body", "#text": "Department of Defense", "@entity-id": "9700"}, {"#tail": " to increase research and improve patient care regarding FGIMDs\n\t\t\t\tthat commonly impact veterans and active duty military personnel, such as IBS\n\t\t\t\tand\n\t\t\t\tdyspepsia.", "@entity-type": "federal-body", "#text": "Department of\n\t\t\t\tVeterans Affairs", "@entity-id": "3600"}], "#text": "exploring\n\t\t\t\topportunities to partner with the "}, "enum": {"#tail": "\n            ", "#text": "(6)"}, "@id": "HAA5F8C69C0A44DCEA2B666DEBD7A0AE3", "#text": "\n            "}], "#text": "\n          ", "@id": "HF748F8BC147F462187546DC12FCCBF41"}, "#text": "\n\t\t\t\t", "@id": "H37FCF6E9459E43E19E7823ADD587C776"}, "#text": "\n      ", "@id": "H4ED7ECC83353431BB491002DC1298CFF"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "#text": "\n        ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by adding at the end the\n\t\t\t following:", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "Part B of title III of the Public Health\n\t\t\t Service Act", "@value": "Public Health Service Act/t:III/pt:B"}, {"#tail": ")", "@entity-type": "uscode", "#text": "42 U.S.C. 243 et seq.", "@value": "usc/42/243/etseq"}], "@entity-type": "law-citation", "#text": "\n          "}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "4."}, "header": {"#tail": "\n      ", "#text": "Promoting public\n\t\t\t awareness of functional gastrointestinal and motility disorders"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n      ", "#text": "."}, "#tail": "\n\t\t", "section": {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " may engage in public awareness\n\t\t\t\tand education activities to increase understanding and recognition of\n\t\t\t\tfunctional gastrointestinal and motility disorders (in this section referred to\n\t\t\t\tas ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "term": {"#tail": "). Such activities may include the distribution of print,\n\t\t\t\tfilm, and web-based materials targeting health care providers and the public\n\t\t\t\tand prepared and disseminated in conjunction with patient organizations that\n\t\t\t\ttreat FGIMDs. The information expressed through such activites should\n\t\t\t\temphasize\u2014", "#text": "FGIMDs"}, "#text": "The ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n          ", "#text": "320B."}, "header": {"#tail": "\n          ", "#text": "Public\n\t\t\t\tawareness of functional gastrointestinal and motility disorders"}, "paragraph": [{"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "basic information\n\t\t\t\ton FGIMDs, their symptoms, prevalence, and frequently co-occurring conditions;\n\t\t\t\tand"}, "enum": {"#tail": "\n            ", "#text": "(1)"}, "@id": "H84ED04EBD5434352AEA403A2BBE4AE9E", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "the importance of\n\t\t\t\tearly diagnosis, and prompt and accurate treatment of\n\t\t\t\tFGIMDs."}, "enum": {"#tail": "\n            ", "#text": "(2)"}, "@id": "H32528553159E4BC0AA0156FE62C9DCD1", "#text": "\n            "}], "#text": "\n          ", "@id": "HB2360CBDD3C5499A94FA27A06149AAA8"}, "#text": "\n\t\t\t\t", "@id": "H2DE8E8F30EEB4FCCACE0CDCF819F4162"}, "#text": "\n      ", "@id": "HEE4BA3C57EE04015BA4439D088B2F749"}, {"#tail": "\n  ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " that,\n\t\t\t considering the current lack of effective treatment options for the global\n\t\t\t symptoms of functional gastrointestinal and motility disorders (in this section\n\t\t\t referred to as ", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}, {"#tail": "\n\t\t\t should continue and accelerate important efforts to improve the development and\n\t\t\t oversight of treatment options for FGIMDs by\u2014", "@entity-type": "federal-body", "#text": "Commissioner of Food and Drugs", "@entity-id": "7524"}], "term": {"#tail": ") and the inherent challenges of developing\n\t\t\t and bringing such treatments to market, the ", "#text": "FGIMDs"}, "#text": "It is the sense of ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "5."}, "header": {"#tail": "\n      ", "#text": "Sense of Congress\n\t\t\t on the development and oversight of innovative treatment options for functional\n\t\t\t gastrointestinal and motility disorders"}, "paragraph": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "enhancing the\n\t\t\t commitment to emerging efforts like the Patient Reported Outcomes Consortium to\n\t\t\t expedite medical device and drug development, study appropriate balances\n\t\t\t between risk and patient benefit, and identify proper endpoints for conditions\n\t\t\t without clear, biological indicators;"}, "enum": {"#tail": "\n        ", "#text": "(1)"}, "@id": "H13F1CC71F267416FB2D657E555707344", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "enhancing the\n\t\t\t commitment to broad efforts like the Critical Path Initiative focused on\n\t\t\t ensuring that scientific breakthroughs are quickly translated into safe and\n\t\t\t beneficial treatment options; and"}, "enum": {"#tail": "\n        ", "#text": "(2)"}, "@id": "HA71EED4FD5F74E9396E61D648BB2D27A", "#text": "\n        "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "#text": "continuing collaboration with patient\n\t\t\t organizations that treat FGIMDs so that the patient perspective is considered\n\t\t\t when determining the need for innovative treatments.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(3)"}, "@id": "H4BAF3E5B41DB4CDBB7DE308C904DCFBC", "#text": "\n        "}], "#text": "\n      ", "@id": "H13A1A7F0ACDD425AB653220F0FC326EF"}], "#text": "\n\t\t", "@id": "HF4CCE939F26F414E8C8269AB0CA20C53"}}}